Indaptus Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $326.4M
- Price
- $2.45
- % Change (Daily % change from the live per-ticker quote feed.)
- -8.24%
- Volume
- 156.7K
Quote data as of 6:09 AM ET
About
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Quick stats
Shares outstanding133.2M
Computed float1.4M
Float sourceUnknown
Cash runway (months)-2.3
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001857044
Websitehttps://indaptusrx.com
AI Summary
AI-generated2mo agostandardbearishearningsIndaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Indaptus Therapeutics reported a Q1 2026 net loss of $2.5 million, significantly improved from $4.5 million in the prior year, driven by a sharp reduction in R&D spend to $0.5 million.
Cash reserves have deteriorated rapidly, falling from $8.5 million at year-end to just $1.5 million as of March 31, 2026, with operating cash burn of $7.0 million for the quarter.
The company is undergoing a management transition and strategic review, including headcount reductions and a reassessment of its Decoy platform, while explicitly warning that it needs to raise additional capital with no assurance of success.
Red flags
- Cash balance of $1.5M implies imminent need for dilutive financing or risk of insolvency
- Management transition and strategic review of core platform signal uncertainty
- Headcount reductions and salary cuts indicate financial distress
- Explicit disclosure of 'substantial doubt regarding the Company’s ability to continue as a going concern' in risk factors